Zelluna Immunotherapy AS

Activities: Research & Development Pharmaceutical

Trending Articles

  1. NHS, MHRA and Medicines UK launch Project Revive to tackle medicine shortages NHS England, the MHRA and Medicines UK have launched Project Revive, a collaborative pilot designed to address critical medicines shortages by fast-tracking dormant...
  2. Isopod Rapid Cleanrooms: the ideal elite controlled environment pod solution for Life Sciences and Engineering start-ups The Guardtech Group’s quick-assembly cleanroom pods combine superior performance, build quality and cost-effectiveness to give new applications the perfect platform to get...
  3. You need to be a subscriber to read this article.
    Click here to find out more.
    Delivering precision: why advanced therapies are redefining pharmaceutical logistics As advanced therapies narrow tolerances and personalise care, pharmaceutical logistics is being redefined as a precision-driven extension of treatment delivery, writes Michael...
  4. Nose-to-brain delivery outperforms systemic BBB technologies according to MetP Pharma The pioneering company has published preclinical data that strongly supports the advantages of its proprietary nose-to-brain drug delivery technology compared with systemic...
  5. AstraZeneca strengthens weight management pipeline with CSPC Pharmaceuticals collaboration The pair have signed a strategic collaboration covering eight obesity and type 2 diabetes programmes, including a clinical-ready GLP-1/GIP asset, AI-driven peptide discovery...

Upcoming event

High Shear = Mixing Success

19 February 2026 | Virtual See all

Related Content

Cell & Gene Therapy

Zelluna submits UK clinical trial application and publishes preclinical data for ZI-MA4-1 cell therapy for solid tumours

CTA submission to the UK MHRA and peer-reviewed preclinical results mark Zelluna’s transition into the clinic, with first-in-human data for ZI-MA4-1 expected in mid-2026
Regulatory

Zelluna receives positive MHRA feedback and advances UK clinical plans for ZI-MA4-1

Zelluna has secured alignment with the UK’s MHRA on the clinical and regulatory pathway for its TCR-NK therapy ZI-MA4-1, paving the way for a CTA submission by the end of 2025 and first-in-human trials at The Christie and The Royal Marsden in 2026
Pharmaceutical

Zelluna Immunotherapy appoints Chief Financial Officer
Recruitment

Zelluna Immunotherapy appoints Chief Scientific Officer
Research & Development

Zelluna Immunotherapy appoints Miguel Forte as CEO
Subscribe now